Growth Failure

3

Review clinical trials related to Growth Failure. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Targeted Fortification of Donor Breast Milk in Preterm Infants

This study is a randomized controlled trial comparing standard fortification of donor breast milk to targeted fortification of donor breast milk in preterm infants. The purpose of the study is to determine if there is a benefit to target fortifying donor breast milk in the preterm population. The investigators hypothesize that infants receiving targeted fortification of donor breast milk will have improved growth compared to infants receiving standard fortification of donor breast milk.

Participants needed: 50
Trial details
Age: 1-21Biological sex: AllType: InterventionalSponsor: Columbia UniversityUpdated: Apr 7, 2026Locations: 1
Eligibility criteria

Premature infants born </= 30 weeks gestational age [+1]

Parents do no consent to donor milk [+6]

Status: Not yet recruiting

Impact of Colostrum Oropharyngeal Immunotherapy on Postnatal Growth in Preterm Infants

The goal of this clinical trial is to ascertain whether oropharyngeal administration of colostrum contributes to postnatal growth in very preterm infants (those born before 32 weeks of gestation). The main questions it aims to answer are: Can Oropharyngeal administration of colostrum effectively lower the incidence rate of extrauterine growth restriction (EUGR) in participants? Does oropharyngeal colostrum intervention bring about changes in the early gut microbiota of participants? Researchers will conduct a comparative analysis between colostrum and a placebo (normal saline) to investigate whether oropharyngeal administration of colostrum has a beneficial effect on the postnatal growth of participants. Participants will: Initiation of oropharyngeal colostrum administration will take place within 48 - 72 hours after birth, and the treatment will be administered continuously for a period of 5 days. Stool samples will be collected from the participants both before and after the intervention. Participants will be required to maintain a diary to document their basic characteristics and clinical outcomes.

Participants needed: 220
Trial details
Age: 0-1Biological sex: AllType: InterventionalSponsor: Suqian First HospitalUpdated: Jul 24, 2025
Eligibility criteria

Gestational age <32 weeks and birth weight <1500 g; [+2]

Death within 48 h; [+4]

Status: Not yet recruiting

MAL-ED Metabolic: A Follow-Up of Chronic Disease at Puberty

The concept that the roots of cardiometabolic disease start in early life was established by Dr. David Barker, who documented relationships between low birthweight (as a marker for challenges during gestation) and later cardiovascular disease (CVD). Later work has suggested that post-natal challenges (similar to prenatal ones) may also exhibit links to later cardiometabolic disease, with the strongest links appearing to be between low weight in early childhood and later hypertension and high waist circumference (WC). However, assessments for the relationship between early childhood challenges and insulin resistance and glucose regulation have been lacking and long-term cohort studies are few. In this project, we aim to assess children initially followed as part of The Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health (MAL-ED) study, where they received frequent measures of anthropometry and laboratory assessments for intestinal pathogens. These children are now of peri-pubertal age--a time period associated with metabolic shifts. We will assess for glucose dysregulation and findings associated with the metabolic syndrome, and we will analyze potential associations between current chronic disease risk findings with early life poor growth and intestinal pathogen carriage rate. As such, we hope to uncover potential targets in early life health to reduce later chronic disease risk.

Participants needed: 254
Trial details
Age: 9-17Biological sex: AllType: ObservationalSponsor: University of VirginiaUpdated: Nov 16, 2021
Eligibility criteria

Participated in original MAL-ED cohort

Did not participate in original MAL-ED cohort